




SUBSTITUTE FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 13774-002001												
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371														
INTERNATIONAL APPLICATION NO. PCT/CN00/00164	INTERNATIONAL FILING DATE 19 June 2000	PRIORITY DATE CLAIMED 18 June 1999												
U.S. APPLICATION NO. (If Known, see 37 CFR 1.5) 10/018981														
TITLE OF INVENTION THE LEAVES OF CAJANUS CAJAN(L.) MILLSP AND EXTRACT, FORMULATION AND USES THEREOF														
APPLICANT(S) FOR DO/EO/US Hao Yuan														
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:														
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 														
Items 11 to 16 below concern other documents or information included:														
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 														
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center; padding: 2px;">CERTIFICATE OF MAILING BY EXPRESS MAIL</td> <td style="text-align: right; padding: 2px;">Express Mail Label No. <u>EL485781819US</u></td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 2px;">I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and addressed to the Commissioner for Patents, Washington, DC 20231.</td> </tr> <tr> <td style="text-align: center; padding: 2px;">12-18-01</td> <td style="text-align: center; padding: 2px;">Date of Deposit</td> <td style="text-align: center; padding: 2px;">Signature </td> </tr> <tr> <td colspan="2"></td> <td style="text-align: center; padding: 2px;">Leroy Jenkins Typed Name of Person Signing</td> </tr> </table>			CERTIFICATE OF MAILING BY EXPRESS MAIL		Express Mail Label No. <u>EL485781819US</u>	I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and addressed to the Commissioner for Patents, Washington, DC 20231.			12-18-01	Date of Deposit	Signature 			Leroy Jenkins Typed Name of Person Signing
CERTIFICATE OF MAILING BY EXPRESS MAIL		Express Mail Label No. <u>EL485781819US</u>												
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and addressed to the Commissioner for Patents, Washington, DC 20231.														
12-18-01	Date of Deposit	Signature 												
		Leroy Jenkins Typed Name of Person Signing												

U.S. APPLICATION NO. (IF KNOWN)

10701890

INTERNATIONAL APPLICATION NO.
PCT/CN00/00164ATTORNEY'S DOCKET NUMBER
13774-00200117. The following fees are submitted:**Basic National Fee (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$1,040.00

Surcharge of \$130 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$0.00

Claims	Number Filed	Number Extra	Rate
Total Claims	15 - 20 =	0	x \$18
Independent Claims	3 - 3 =	0	x \$84
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$280

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,040.00

 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$520.00

SUBTOTAL =

\$520.00

Processing fee of \$130 for furnishing the English Translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$0.00

TOTAL NATIONAL FEE =

\$520.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$0.00

TOTAL FEES ENCLOSED =

\$520.00

Amount to be refunded: \$**Charged: \$**

- A check in the amount of \$520.00 to cover the above fees is enclosed.
- Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Y. Rocky Tsao
FISH & RICHARDSON P.C.225 Franklin Street
Boston, Massachusetts 02110-2804
(617) 542-5070 phone
(617) 542-8906 facsimile*Y. Rocky Tsao*
SIGNATURE:

NAME

Y. Rocky Tsao

REGISTRATION NUMBER

34,053

531 Rec'd PCT/US 18 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hao Yuan
Serial No. : Unassigned
Filed : Herewith
Title : THE LEAVES OF CAJANUS CAJAN(L.) MILLSP AND EXTRACT,
FORMULATION AND USES THEREOF

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend preliminarily the above-captioned application as follows:

In the claims:

Amend claims 4-14 as follows:

--4. (Amended) The method of treating osteoporosis, ischemic necrosis of caput femoris, angina of coronary heart disease, fracture, cerebral infarction, bedsores, infected surface of wound, or the infected surface of wound of open fracture, inflammation; ameliorating hemorheological index; reinforcing immunological function; or effecting analgesia, the method comprising administering to a subject in need thereof leaves of *Cajanus Cajan (L.) Millsp.* or the extract thereof.--

--5. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating ischemic necrosis of caput femoris.--

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL485781819US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 12-18-01Signature Henry JenkinsTyped or Printed Name of Person Signing Certificate Henry Jenkins

--6. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for the ameliorating hemorheological index.--

--7. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating inflammation or effecting analgesia.--

--8. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for reinforcing of immunological function.--

--9. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating angina of coronary heart disease.--

--10. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating fracture.--

--11. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating cerebral infarction.--

--12. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating bedsores.--

--13. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating infected surface of wound.--

--14. (Amended) The method of claim 4, wherein the leaves or the extract thereof is for treating the infected surface of wound of open fracture.--

Applicant : Hao Yuan
Serial No. : Unassigned
Filed : Herewith
Page : 3

Attorney's Docket No.: 13774-002001 / I01113/US

Add claim 15.

--15. (New) The method of claim 4, wherein the leaves or the extract thereof is for treating osteoporosis.--

五〇四

Applicant : Hao Yuan
Serial No. : Unassigned
Filed : Herewith
Page : 4

Attorney's Docket No.: 13774-002001 / I01113/US


REMARKS

Claims 1-15 are pending in the application. Claims 4-14 have been amended, and claim 15 has been added. The amendments have been made to, among others, reduce the number of the independent claims while conserving the claimed subject matter. Note that new claim 15 is merely a revised version of original claim 4, now amended. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050 referencing attorney docket no. 13774-002001.

Respectfully submitted,


Y. Rocky Tsao
Reg. No. 34,053

Date: 12-18-01
Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

531 Rec'd PCT 18 DEC 2001

Version with markings to show changes made

In the claims:

Claims 4-14 have been amended as follows:

4. (Amended) The [use] method of treating [of leaves of *Cajan* (*L.*) Millsp or extract thereof for the manufacture of a medicament for the treatment of] osteoporosis, ischemic necrosis of caput femoris, angina of coronary heart disease, fracture, cerebral infarction, bedsores, infected surface of wound, or the infected surface of wound of open fracture, inflammation, ameliorating hemorheological index, reinforcing immunological function, or effecting analgesia, comprising administering to a subject in need thereof leaves of *Cajan* (*L.*) Millsp, or extract thereof.

5. (Amended) The [use] method of claim 4, wherein the leaves [Leaves of *Cajan* (*L.*) Millsp.] or the extract thereof is for [the manufacture of a medicament for the treatment of] treating schemic necrosis of caput femoris.

6. (Amended) The [use] method of claim 4, wherein the leaves [Leaves of *Cajan* (*L.*) Millsp.] or the extract thereof is for [the manufacture of a medicament for the amelioration of] ameliorating hemorheological index.

7. (Amended) The [use] method of claim 4, wherein the leaves [Leaves of *Cajan* (*L.*) Millsp.] or the extract thereof is for [the manufacture of anti-inflammatory] treating inflammation and [analgesic agent] effecting analgesia.

8. (Amended) The [use] method of claim 4, wherein the leaves [Leaves of *Cajan* (*L.*) Millsp.] or the extract thereof is for [the manufacture of a medicament for the reinforcement of] reinforcing immunological function.

The Leaves of Cajanus Cajan(L.)Millsp and Extract.
Formulation and Uses thereof

TECHNICAL FIELD

The invention relates to leaves of Cajanus Cajan(L.)Millsp and extract ,and pharmaceutical formulations thereof. The invention also relate to new uses of leaves of Cajanus Cajan(L.)Millsp and extract , especially in pharmaceutical filed. The invention belongs to field of Chinese Traditional Medicine.

BACKGROUND OF THE INVENTION

Cajanus Cajan(L.)Millsp is a subtropical bush plant, which belongs to adjonus genus of popilionaccae family, grows in south part of China, and also is called as Liudou, Niudou, Dourong or Liudian in Chinese. The plant has effects of clearing away heat and detoxicating, promoting blood circulation and relieving blood stasis, antiseptic, relieving inflammatory. Its root has effects of clearing away heat and detoxicating, stopping bleeding and relieving pain, and killing parasites. The tender leaves of it can be used in treating aphtha when chewed in mouth.; the juice pressed from its tender leaves can be used in treating jaundice; the pulp obtained by pounding its tender leaves have the function of eliminating slough and promoting tissue regeneration on wound ; the decoction of its leaves can be effective in cough and diarrhea. CN 1174052A disclosed medical use of Cajanus Cajan(L.)MillsP, however, it is not clear to obtain active component of the plant because it was used in combination with other components and wasn't extracted. Therefor, its use is limited.

DESCRIPTION OF THE INVENTION

It is an object of the invention to provide an extract from leaves of Cajanus Cajan(L.)Millsp , so-called its active component.

It is a further object of this invention to provide a process for the preparation of such extract.

It is also a object of this invention to provide an pharmaceutical formulation comprising leaves of Cajanus Cajan(L.)Millsp or its extract as active component.

It is another object of this invention to provide new use of leaves of Cajanus Cajan(L.)Millsp or its extract, that is new use in the prparation of pharmaceutical formulations.

The extract of leaves of Cajanus Cajan(L.)Millsp can be obtained as follows:

(1)The purification and preparation of crude materials

Cajanus Cajan(L.)Millsp

[preparation] :The tender leaves and branches of Cajanus Cajan(L.)Millsp is collected, removed impurity and old branches, cleaned and dried in the shade. They are cut into about 5cm small parts and put in clean container for later use.

(2)extraction, concentrating and drying of drugs

These treated Cajanus Cajan(L.)Millsp are put in multi-function extractor. Water is added in 10-fold amount of drugs, and then these drugs are immersed for about 0.5 to 2 hours. The mixture is decocted 1-4 times for 1-2 hours each times. After filtered, the filtrates is drew immediately into a vacuum concentrator(atmospheric pressure is -0.08Mpa and temperature is 60 °C) and concentrated to relative density of 1.05-1.15(detected at 60°C). After filtered with 80 mush filter cloth, the filtrates is filtered by continuous centrifugation, and then the centrifugal fluid is dried by spray-drying process to obtain dried extract powder, that is the active component extract according to the invention which is put in clean and air-tight container.

In order to produce extract according to the invention, the preferable process includes the following steps. These treated Cajanus Cajan(L.)Millsp are put in multi-function extractor. After water is added in 10-fold amount of drugs and these drugs are immersed for about 1 hour, the mixture is decocted 3 times for 1.5 hours each times. After filtered, the filtrates is drew immediately into a vacuum concentrator and concentrated under the condition of -0.08Mpa and 60°C to relative density of 1.05-1.15(detected at 60°C). After filtered with 80 mush filter clothes, the filtrates is filtered by continuous centrifugation at 15,000r.p.m with the flow amount of 50L/hour, and then the centrifugal fluid is dried by spray-drying process under the condition of 180°C at entrance, 4 seconds of dried time and 80°C at exit. The resultant dried extract powder is put in clean and air-tight container.

The extract of leaves of Cajanus Cajan(L.)Millsp can be formulated into pharmaceutical formulations for clinic use such as tablets, pills, powders, capsules, oral liquids and so on by standard methods, in which the extract is present as active component at effective therapeutic amount, in generally range from 0.01 to 99.9%, preferably, 1 to 90%, more preferably from 5 to 80%, most preferably from 10 to 70%. Alternatively, dried leaves of Cajanus Cajan(L.)Millsp can be ground to powder as active component to formulated into clinic pharmaceutical formulations by standard methods.

The capsule of leaves of Cajanus Cajan(L.)Millsp can be produced by mixing the extract optionally with excipient such as starch and filling into capsule.

It is confirmed by tests that leaves of Cajanus Cajan(L.)Millsp or extract thereof have the following novel medical uses.

1.the use of leaves of Cajanus Cajan(L.)Millsp or extract thereof for manufacture of a medicament for the treatment of osteoporosis

In order to observe the effect of the capsule of leaves of Cajanus Cajan(L.)Millsp on experimental osteoporosis, the osteoporosis model is made by tretinoin. The result indicated that the capsule notably increased levels of calcium and phosphorus in serum, decreased the level of alkaline phosphatase, and enhanced BMC and BMD in rats. From the observation on pathological section, it is showed that the capsule

significantly improved the quality of bone trabecula, reduced the numbers of osteoclast and promoted the growth of osteoblast and thereby prevented and treated osteoporosis

2. The use of leaves of *Cajanus Cajan*(L.)Millsp or extract thereof for manufacture of a medicament for the treatment of ischemic necrosis of caput femoris

After established the New Zealand rabbit model of ischemic necrosis of caput femoris by horse serum-hormone, the capsule at high, middle and low dosages was administrated to the animals separately, normal control group and model control group were set simultaneously. The result showed that the capsule had notable effect on treatment of hormone-induced ischemic necrosis of caput femoris after detecting the density of bone tissue in proximal end of femur, observing by magnifying X-ray photo, pathologic examination by light microscope, observing under television microscope and dynamic measurement for metabolism of bone tissue.

3. The effect of leaves of *Cajanus Cajan*(L.)Millsp or extract thereof on the improvement of hemorrhheology

The test of microcirculation in rat mesentery demonstrated that the capsule can significantly increase velocity of blood flow, infinitesimal calculus of velocity and state of blood flow. The index of hemorrhheology for rat acute hypostasis model displayed that the capsule can enhance the specific viscosity of total blood and plasma and decrease blood sedimentation.

4. The use of leaves of *Cajanus Cajan*(L.)Millsp or extract thereof for manufacture of a medicament for anti-inflammatory and analgesicization

The tests of dimethylbenzene induced inflammation on mice pinna and cotton ball granuloma on mice showed that the capsule can alleviated notably ear tumefaction reduced by dimethylbenzene and cotton ball granuloma. Tests of torsion method and hot plate method on mice showed that the capsule declined clearly the number of torsion mice, prolonged the period of the first torsion, increased percent of analgesis, and increased threshold value of pain on mice.

5. The use of leaves of *Cajanus Cajan*(L.)Millsp or extract thereof for manufacture of a medicament for enhancement of immune function

Mice were induced by prednisone acetate to low immune function. In these models, the capsule according to the invention not only have the trend of enhancing phagocytic function of mononuclear leukocyte in mice, but also increased markedly the weight of immune organs such as thymus, spleen and the level of hemolysin in mice in which chicken red blood cell acts as immunogen. In addition, It significantly increased the present rate of transition state T-lymphoblastoid cell and the rate of transformation of lymphocyte stimulated by phytohemagglutinin in mice.

6. The use of leaves of *Cajanus Cajan*(L.)Millsp or extract thereof for manufacture of a medicament for the treatment of bed sore

It can be seen by clinical observation that the curative effect of leaves of *Cajanus Cajan*(L.)Millsp and extract thereof are superior to that of traditional ointment for promoting muscle growth on treatment of bed sore. The leaves of *Cajanus Cajan*(L.)Millsp and extract thereof can not only shorten course of treatment, but also decrease the scar after healing.

7. The use of leaves of Cajanus Cajan(L.)Millsp or extract thereof for manufacture of a medicament for the treatment of infected wound

The leaves of Cajanus Cajan(L.)Millsp and extract thereof have effects of promoting the growth of epithelium granulation tissue on surface of wound, increasing supply of blood to surface of wound, speeding up wound healing, decreasing growth of scar tissue, and enhancing the quality of healing. As far as anti-infectious effect is concerned, it can be found that leaves of Cajanus Cajan(L.)Millsp and extract thereof have good effect against infection on infected wound, which is manifested by quickly disappear of wound and inflammatory reaction, especially by decreasing rapidly the exudation on surface of wound after administration and clean surface of wound, it is implied that the medication has good effect on resisting inflammatory exudation.

8. The use of leaves of Cajanus Cajan(L.)Millsp or extract thereof for manufacture of a medicament for the treatment of infected wound of open fracture

The leaves of Cajanus Cajan(L.)Millsp and extract thereof have good effect of anti-infection in clinical test and can promote the growth of granulation tissue, increase the supply blood for wound surface, enhance the healing of wound surface, particularly the growth of granulation tissue, as called "granulation island of bone", on the bone surface exposed to wound surface.

The results of clinical treatment also showed that the leaves of Cajanus Cajan(L.)Millsp and extract thereof have good curative effect on angina pectoris of coronary heart disease, cerebral infarction, and fracture.

In order to understand the essence of the invention further, the process of producing the extract of Cajanus Cajan(L.)Millsp, the pharmacological study of leaves of Cajanus Cajan(L.)Millsp and extract thereof as well as the results of study will be described in detail by means of the following examples so as to illustrate the novel uses in pharmaceutical field.

THE BEST EMBODIMENT OF THE INVENTION

Example 1. Process of producing extract from leaves of Cajanus Cajan(L.)Millsp and the capsule thereof

10kg crude leaves of Cajanus Cajan(L.)Millsp was weighted from same batch and cut to sections. Water was added in amount of 10 fold and heated to decoct 3 times, 1.5 hours each times. After filtration, these filtrates are combined and concentrated in vacuum to relative density 1.15 under -0.08Mpa and 60°C. precipitation was removed away by centrifugation(15000r.p.m), and the resulting filtrate was dried to yield extract powder (0.81kg) by spray drying process. The obtained extract powder was laid in clean and air tight container for later use.

The dried extract powder of leaves of Cajanus Cajan(L.)Millsp as above was filled into pharmaceutical capsule to obtain capsule preparation, which will be called as Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule) in next context.

Experimental example 2. The pharmacological effect of preparations of leaves of Cajanus Cajan(L.)Millsp on treating osteoporosis

- 1. Test of pathologic change in bone induced by tretinoin

Materials

Medicaments: Capsule of Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule); tretinoin, produced by the 6th pharmaceutical factory of SHANGHAI, Number of batch: 960322; Powder of LONGMU ZHUANGGU, produced by JIANMIN pharmaceutical factory of WUHAN, Number of batch: 960111.

Animals: 100 male SD rats, supplied by the animal feedlot of the health department of guangdong province, body weight: 250-300g; certificate number : 96A02

Feeds: Standard feeds provided by the animal feedlot of the health department of guangdong province.

Equipment: KANGNING type of US: 55 automatic biochemical analyzer, TECHNICON, RA2000, DEXA (HologicQDR-2000 operators Manual) from US.

Regents: TRACE from Australia (sell from Longmarch company of SHANGHAI)

Methods and Results

Animals were randomly divided into six groups which include control group, model group, LONGMU ZHUANGGU-group ,Shengmaichenggu Capsule-group in three dosages (the dosage is respectively 7.68g/kg/day, 3.84g/kg/day , 1.92g/kg/day and the amount of crude drugs used in clinic was 1g/kg/day). After model group, LONGMU ZHUANGGU-group and three Shengmaichenggu Capsule-group were administrated with tretinoin 70mg/kg/day simultaneously and medicaments for 2 weeks by filling into stomach, the administration of tretinoin was stopped. The LONGMU ZHUANGGU -group and the three Shengmaichenggu Capsule-group were continuously administered for 5 weeks. Distilled water was administered in 20ml/kg/day for control group and model group. Each item was tested as follow.

(1)Contents of calcium, phosphorus, and alkaline phosphatase(AKP) in serum

5ml blood were taken from eyeball of rats in the morning. The contents of calcium, phosphorus, and alkaline phosphatase in serum were determined by 550 automatic biochemical analyzer, TECHNICON, RA2000 of US with TRACE of Australia. The result was listed in following table 1.

As shown by the result, The content of phosphorus in serum of model group dropped significantly ($p<0.001$) compared with that of control group. The contents of calcium and phosphorus of the three Shengmaichenggu Capsule-group at high, middle and low dosage increased notably ($p<0.001$, $p<0.01$, or $p<0.05$) Compared with that of model group. The content of alkaline phosphatase in serum of Shengmaichenggu Capsule-group at low dosage decreased significantly ($p<0.05$) compared with that of model group.

(2) The bone area(AREA),bone mineral density(BMD), bone mineral content(BMC) tested by double photon bone density assay,

The AREA, BMD, and BMC of rats were determined by DEXA (Hologic QDR-2000 operators Manual) under anesthesia by pentobarbital sodium. The AREA, BMD, and BMC of rats were determined at point of global (whole rat), R1 (left head of femur), R2 (right head of femur), R3 (right femur), R4 (left femur), R5 (lumbar

vertebra), and NETAVG (the sum of R1, R2, R3, R4,R5) . (the result was showed in table2 and 3).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
289
290
291
292
293
294
295
296
297
298
299
299
300
301
302
303
304
305
306
307
308
309
309
310
311
312
313
314
315
316
317
318
319
319
320
321
322
323
324
325
326
327
328
329
329
330
331
332
333
334
335
336
337
338
339
339
340
341
342
343
344
345
346
347
348
349
349
350
351
352
353
354
355
356
357
358
359
359
360
361
362
363
364
365
366
367
368
369
369
370
371
372
373
374
375
376
377
378
379
379
380
381
382
383
384
385
386
387
388
389
389
390
391
392
393
394
395
396
397
398
399
399
400
401
402
403
404
405
406
407
408
409
409
410
411
412
413
414
415
416
417
418
419
419
420
421
422
423
424
425
426
427
428
429
429
430
431
432
433
434
435
436
437
438
439
439
440
441
442
443
444
445
446
447
448
449
449
450
451
452
453
454
455
456
457
458
459
459
460
461
462
463
464
465
466
467
468
469
469
470
471
472
473
474
475
476
477
478
479
479
480
481
482
483
484
485
486
487
488
489
489
490
491
492
493
494
495
496
497
498
499
499
500
501
502
503
504
505
506
507
508
509
509
510
511
512
513
514
515
516
517
518
519
519
520
521
522
523
524
525
526
527
528
529
529
530
531
532
533
534
535
536
537
538
539
539
540
541
542
543
544
545
546
547
548
549
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
997
998
999
999
1000

Table 1. the effect of capsule of SHENGMAI CHENGU on contents of calcium, phosphorus, and alkaline phosphatase in serum (x±s)

Group	Numbers of animal	Dosage(kg/day)	P	Ca	AKP
Control group	6	20ml distilled water	2.53±0.12	2.15±0.29	329.17±32.30
Model group	8	20ml distilled water	2.13±0.20***	1.91±0.35	334.38±97.63
LONGMU ZHUANGGU-group	8	5g	2.49±0.19###	2.14±0.17	341.75±37.48
Shengmaichenggu Capsule-group	8	7.68g	2.48±0.15###	2.24±0.22#	319.13±49.43
Shengmaichenggu Capsule-group	8	3.84g	2.45±0.12###	2.29±0.24##	282.13±26.22
Shengmaichenggu Capsule-group	8	1.92g	2.42±0.11###	2.56±0.36###	304.15±64.72#

Note: *P<0.05, **P<0.01, #P<0.05, ##P<0.01

*P<0.05 when model group is compared with control group. ** P<0.01 when model group is compared with control group, *** P<0.001 when model group is compared with control group.

P<0.05 when positive medicament group or Shengmaichenggu Capsule-group is compared with model group. ## P<0.01 when positive medicament group or Shengmaichenggu Capsule-group is compared with model group. ### P<0.001 when positive medicaments group or Shengmaichenggu Capsule-group is compared with model group.

The indication of signals in the following tables is same as that in Table 1 except annotation otherwise.

100% Tencel®

Tables 2. The effected of Shengmaichenggu Capsule-group on AREA, BMD, and BMC in Globan rats.

Group	Number of animal	Dosage (kg/day)	Global			Area	BMD	Area	BMC	Area	RS
			Area	BMD	Global						
Control group	5	20ml distilled water	56.4128±5.1772	0.1125±0.6180	0.1125±0.00356	2.70206±0.7508	0.36934±0.1073	0.13592±0.00383	0.1145±0.013**	0.1145±0.013**	
Model group	5	20ml distilled water	48.2582±6.2002**	0.10524±0.7169***	0.10468±0.00386***	2.7089±0.2626	0.31124±0.0522	0.1145±0.013**	0.1145±0.013**	0.1145±0.013**	
Shengmatchenggu Capsule-group	5	5g	55.2327±3.4762#	0.12946±0.6382##	0.11372±0.00356##	3.01614±0.6008	0.3878±0.1189	0.12664±0.0136	0.12664±0.0136	0.12664±0.0136	
Shengmatchenggu Capsule-group	5	7.68g	54.1496±3.7743#	0.10855±0.6666#	0.11228±0.00490#	3.02076±0.1870	0.3958±0.165	0.13082±0.00456#	0.13082±0.00456#	0.13082±0.00456#	
Shengmatchenggu Capsule-group	5	3.34g	58.5560±2.6876##	0.63388±0.2893###	0.11342±0.00393##	3.03232±0.3288	0.3995±0.00269	0.13223±0.00643#	0.13223±0.00643#	0.13223±0.00643#	
Shengmatchenggu Capsule-group	5	1.92g	49.3117±4.0395	5.5338±0.6037	0.11074±0.00316	2.7759±0.5044	0.3367±0.0692	0.12866±0.014#	0.12866±0.014#	0.12866±0.014#	

As shown by the results, AREA, BMC and BMD of Global in model groups remarkably dropped ($P<0.001$, $P<0.01$ or $P<0.05$) compared with that of control group. Whereas AREA, BMC and BMD of Global in Shengmaichenggu Capsule-group at high, middle dosage remarkably increased ($P<0.001$, $P<0.01$ or $P<0.05$) compared with that of model group. BMD of R5 in model group remarkably reduced ($P<0.01$) compared with control group, BMD of R5 in Shengmaichenggu Capsule-group increased significantly ($P<0.05$) compared with model group, BMC and AREA of Shengmaichenggu Capsule-group have the trend of increasing compared with model group.

Table 3. The effects of Shengmaichenggu Capsule-group on NETAVG AREA, BMC, BMD, in rats

Group	NETAVG				
	Case	Dosage (kg/day)	Area	BMC	BMD
Control group	5	20ml distilled water	5.1039±0.9459	0.6701±0.1478	0.13056±0.00563
Model group	5	20ml distilled water	5.0508±0.3066	0.5656±0.0647	0.11190±0.01000**
Shengmaichenggu Capsule-group	5	5g	5.3048±0.9553	0.6645±0.1997	0.12322±0.01490
Shengmaichenggu Capsule-group	5	7.68g	5.5173±0.2050#	0.6858±0.0563	0.12416±0.00626#
Shengmaichenggu Capsule-group	5	3.84g	5.5819±0.4001	0.7006±0.0647	0.12546±0.00542#
Shengmaichenggu Capsule-group	5	1.92g	5.2240±0.6167	0.6369±0.0854	0.12156±0.01010

As shown in results, the BMD of NETAVG in model group decreased markedly ($P<0.01$) compared with that of control group, the BMD of Shengmaichenggu Capsule-group at high and middle dosage increased markedly ($P<0.05$) compared with that of model group. BMC and AREA of Shengmaichenggu Capsule-group have the trend of increasing compared with that of model group.

(3) Examination of histomorphology

Method

The head of Femur was cut along coronal section of the head of femur and cross section of midpiece of femur, fixed with 10% formalin buffer and washed with running water after decalcification with 5% nitric acid. After imbed with paraffin, it was cut and stained with HE. Bone trabecula, osteoblast and osteoclast in HE section of bone were observed to see whether any changes occur.

Results

Normal control group: regular and compact bone trabecula without fragmentation were observed.

Model group: bone trabecula became slender and smaller with fragmentation, the structure became disorder, even disappear. Hematopoietic cell reduced obviously. Medullary cavity enlarged; osteoblast decreased obviously, and osteoclast increased obviously.

LONGMU ZHANGGU Group: The structure of bone trabecula was irregular, but it didn't become slender obviously. Osteoblast increased as compared with that of model group, the increase of osteoclast is not obviously.

Shengmaichenggu Capsule-group at high dosage: The structure of bone trabecula was normal and regular, didn't become slender and smaller; hematopoietic cell was abundant; osteoblast increased, osteocalst reduced.

Shengmaichenggu Capsule-group at middle dosage: The structure of bone trabecula was almost normal and regular, didn't become slender and smaller; hematopoietic cell was relative abundant; Medullary cavity enlarged didn't enlarged obviously; osteoblast increased, the increase of osteocalst is not obvious.

Shengmaichenggu Capsule-group at low dosage Group: The structure of bone trabecula was almost normal and regular, didn't become slender; osteoblast increased slightly, the increase of osteocalst is not obvious.

Summary:

The above experiments discussed the prophylaxis and treatment effects of Shengmaichenggu Capsule on osteoporosis induced by tretinoin. The result showed that Shengmaichenggu Capsule can raise the contents of calcium and phosphorus in blood serum, promoted the growth of osteoblast, improved the quality of bone trabecula, increased bone mineral content and bone mineral density. These indicated that the medicament of the invention have the effect of reinforcing vital energy and strengthening bone to prevent the occurrence of osteoporosis.

2.Clinical observation of the effect of capsule of leaves of Cajanus Cajan(L.)Millsp on treating osteoporosis.

Clinic information

200 patients were chosen, in which there were 78 male and 122 female. 9 patients were 45-50 year old. 28 patients were 51-60 year old. 122 patients were 61-70 year old. 34 patients were 71-80 year old. 7 patients were 81-99 year old. Their average age was 65 year old. Their chief complaints included spontaneous ostealgia which occurred continually or occasionally in different degree. The patients usually had backache or pain in hip and knee joint, felt aching and weak in loin and knee. When tired, the above symptoms became heavier. The patients can not sit for a long time and were easy to be fatigue. Their activity was hindered and restricted. Even someone often need taking analgesic in order to relieve their pain, but the effect is not satisfied or the pain recurred after stopping administration. Their courses of treatment were within 3 months to 3.5 years and average course was 9 months. By physic examination, it was found that 127 patients had hump back or deformity of kyphosis in varying degree, 132 cases were accompanied with tenderness and percussion pain on vertebrae, percussion pain on hip and knee joint. By examination with X-ray, it was found that there were 112 cases with spinal compression fracture, 15 cases with hip fracture, 27 cases with wrist fracture, 5 cases with arm fracture, 6 cases with multiple fracture. All patients showed obvious symptom of osteoporosis such as low bone density ,thin cortex of bone, slender and sparse bone trabecula without other possibility of pathologic fracture such as other disease or metastatic carcinoma.

Method of treatment

(1)General therapy: those who had slight compression fracture or center depressed compression fracture on spine needn't lie in bed. Those whose vertebral body was

compressed about $\leq 1/3$ need lie in bed for two weeks. Those whose vertebral body was compressed about $\geq 1/2$ or many vertebral body was compressed to be deformed and had bad stability need lie in bed for 3-5 weeks. All of the patients need small pillows under the center of injured vertebrae so as to relieve deformity of ihyocyphos in late time. Those who had hip fracture need therapy of bone traction or fixing with screw nail. Be careful to prevent from bed sore and infection in lung and urinary system during time of lying in bed.

(2)Treatment with Shengmaichenggu Capsule by oral administration

(3)Accessory therapy

Patients are encouraged to maintain activity outdoor during middle and later period in order to increase bone stress stimulation, enhance the bone firm and tenacious so as to make bone strong and make joints agile. Don't let the patients do excising violently and carry heavy goods. Those who had fracture should combine other therapies, for example, infrared radiation, TDP lamp irradiation and fumigation with traditional Chinese medicine in order to promote healthy.

Treatment result

(1)Standard of evaluating curative effect

Notable effect: It means that all clinical symptoms disappeared, normal activity functions were obtained, fracture was healed, or compress-deformed vertebral body recovered partly, and symptoms of osteoporosis are improved.

Improved effect: A majority of clinical symptoms disappeared, fracture healed or heal was delayed, compression of vertebral body didn't become serious, symptoms of osteoporosis are improved or changed unclearly, daily activity can be restored; or main clinical symptoms disappeared, activity function improved obviously.

Invalid : Main clinical symptoms, physical signs such as bone pain symptom, activity function and osteoporosis all were not improved or became serious.

(2)Results of curative effect

According to above standard of evaluating curative effect, results was that there were 89 cases with notable effect, 29 cases with improved effect and total improved effect rate was 85.5%after 2-5 month treatment. 63 of the patients were visited during 3-5 years, and non of them has fracture again and their body condition recovered very well. 38 patients who had suffered vertebral body compress fracture have restored the ability of labour.

Experimental example 3. Observation on effect of the capsule of leaves of Cajanus Cajan(L.)Millsp on angina pectoris of coronary heart disease

1. Clinical information

45 patients were treated, in which 30 patients were male and 15 patients were female. Among them, the oldest patient was 75 years old, the youngest patient was 38 years old and average ages was 54 years old; The shortest course of treatment was 1 month, the longest course of treatment was 10 years and average course was 38 months.

According to the diagnose standard of coronary heart disease made by WHO in 1981 and the standard of naming and diagnosing coronary heart disease made by experts group of coronary heart diseases in the first national conference of internal medicine in 1980, 37 patients who had suffered from exertional angina pectoris was diagnosed in different degree which include 5 patients as degree I, 16 patients as degree II, 10 patients as degree III and 6 patients as degree IV. 8 patients had suffered from spontaneous angina pectoris, among them 16 patients also suffered from kinds of arrhythmia.

2. Method of treatment

All patients were treated with Shengmaichenggu Capsule and their electrocardiogram were checked before and after treatment.

3. Standard of curative effect and treatment results

(1) Standard of curative effect

The standard of curative effect on angina pectoris of coronary heart disease revised by national symposium on preventing and treating angina pectoris of coronary heart disease and arrhythmia by methods of traditional Chinese medicine and Western medicine on September, 1979 is incorporated as reference here.

(2) Treatment results

The effect on angina pectoris symptom: there were 29 cases with notable effect, 15 cases with improved effect and 1 case with invalid effect; The effect on electrocardiogram: there were 13 cases with notable effect, 16 cases with improved effect and 16 cases with invalid effect. As far as accompanied symptom of arrhythmia, majority of patients had disappeared or reduced obviously.

Experimental example 4. The effect of capsule of leaves of Cajanus Cajan(L.) Millsp on treating cerebral infarction

1. General information

60 patients were chosen who conformed to the standard of diagnose and evaluation of curative effect on apoplexy according to traditional Chinese medical science and were diagnosed by CT examination. They were divided into two groups in which there were 32 patients in treated group including 23 male patients and 9 female patients. Their ages were from 53 to 78 years old and their average age was 64.8 years old. The course of treatment was from 3 days to 1 month. there was 28 patients in control group including 22 male patients and 6 female patient, whose ages was from 54 to 72 years old, and the average ages was 61.3 years old. The course was from 2 to 7 months.

2. Method of treatment

All patients were treated with SHENGMAICHENGGU capsule. The dosage is that three times every day, 4 capsules one time, and three months is one course. Patients in control group were treated with compound DANSHEN tablets three times one day, three tablets once. All patients were treated for six months. Physiotherapy ,acupuncture and moxibustion therapy was used during recovering period.

3. Observation of curative effect

(1) Standard of curative effect

substantially cured: It means that myodynamia increased more than two degrees, physical sign of nervous system substantially disappeared, and patient could care oneself.

Notable effect: It means that myodynamia increased 1-2 degrees and patient couldn't care oneself.

Invalid effect: It means that myodynamia increased up to one degrees.

(2) Treatment results

In treated group, there were 14 cases substantially cured (43.75%), 13 cases with notable effect (40.63%), 2 cases with effect (6.25%), 3 cases with invalid effect (9.37%), the total effective rate is 90.63%. In the control group, 8 cases substantially cured (28.57%), 11 cases with notable effect (39.29%), 4 cases with effect (14.28%), 5 cases with invalid effect (17.86%), the total effective rate is 82.14%. There is a significant difference between the two groups ($t=3.425, p<0.01$).

Experimental example 5 Clinical observation on the effect of treating fracture by the capsule made from the leaves of *Cajanus cajan*

1. Clinical information

(1) Selected 108 cases suffered from fresh closed limb fracture, in which 60 are male and 48 female, varying in age from 18 to 79 years old, with an average age of 40.8 years old, wherein there were 11 cases with humerus fracture, 30 cases with ulnar fracture, 14 cases with metacarpal fracture, 17 cases with femur fracture, 21 cases with peroneotibial fracture, 15 cases with metatarsophalangeal fracture. The cases were divided into two groups according to the sequence of seeking medical advice. The group with odd numbers was treated group, and that with even numbers was control group. There are 54 cases in each group. The two groups are comparable with substantially similar distribution of age, sex and fracture part ($p>0.05$) (See table 4-6).

Table 4 Age distribution of the two groups

Age(years)	Treated group	Control group	Total
	Cases(%)	Cases(%)	Cases(%)
18-30	16(29.63)	17(31.43)	33(30.56)
31-40	7(12.96)	8(14.81)	15(13.89)
41-50	9(16.67)	7(12.96)	16(14.81)
51-60	10(18.52)	9(16.67)	19(17.59)
61-78	12(22.22)	13(24.07)	25(23.15)

Table 5 Sex distribution of the two groups

Sex	Treated group	Control group	Total
	Cases(%)	Cases(%)	Cases(%)
Male	32(59.26)	28(51.85)	60(55.56)
Female	22(40.74)	26(48.15)	48(44.44)

Table 6 Fracture part distribution of the two groups

Fracture part	Treated group	Control group	Total
	Cases(%)	Cases(%)	Cases(%)
Humerus	5(9.26)	6(11.11)	11(10.19)
Ulnoradial bone	16(29.63)	14(25.93)	30(27.78)
Metacarpophalangeal bone	8(14.81)	6(11.11)	14(12.96)
Femur	9(16.67)	8(14.81)	17(15.74)
Peroneotibial bone	9(16.67)	12(22.22)	21(19.44)
Metatarsophalangeal bone	7(12.96)	8(14.81)	15(13.89)

(2)Method of treatment

The patients of two groups were treated with conventional method of reduction, fixation and function training. Additionally, patients of the treated group took the capsule made from the leaves of Cajanus cajan orally, 4 pills each time, thrice a day. One treatment-course consisted of 15 days. The capsule was administered continually for 1-3 course or even longer according to the patients' condition. The patients of the control group took SANQI(one Chinese herbal medicine) capsule orally, 4 pills each time, thrice a day. One treatment-course consisted of 15 days.

(3) Standard of curative effect : Evaluating the curative effect according to the fracture healing time.

Cure : To reach the clinical healing standard ahead of at least 1/3 period as compared with the time needed for the same type of fracture without the treatment of the invention.

Notable effect: Reach the clinical healing standard ahead of at least 1/4 period as compared with that for the same type of fracture without the treatment of the invention.

Effect: Reach the clinical healing standard ahead of at least 1/5 period as compared with that for the same type of fracture without the treatment of the invention.

Invalid effect: With the same healing period as that for the same type of fracture without the treatment of the invention.

The clinical healing standard and the healing time for fracture took reference to Tong's standards, et al. To evaluate the functional recovery according to Yang's evaluating standard.

Excellent: The fracture is healing. The articulations' moving range is formal or nearly formal. Recover to work;

Good: The fracture is healing. The articulations' move range is more than 30°. The patient Can take care of oneself in daily life.

Bad: The fracture is healing. The articulation moves with obvious difficulty. The forearms can not rotate freely or can not hold heavy objects. The patients have pain at articulations of lower limbs or can not walk with heavy load.

(4)Treatment results :

The cases of each groups underwent 1-3 courses. Comparison of the fracture healing time is shown in table 7. The data were statistically analyzed with χ^2 -test. The

comparison of the total effective rate between two groups showed no significant difference($P>0.05$). But one control case belonged to the bad grade. The excellent-good rate of the control group was slightly lower than that of the treated group.

Table 7 Comparison of the fracture healing time between two groups(day)

Group	Treatment effect				Effective rate(%)
	Cure	Notable effect	Effect	Invalid effect	
Treated	27	15	9	3	94.44
Control	69	10	2	9	46.30

Table 8 Comparison of the function recovery between two groups

Group	Treatment effect				Excellent-good rate (%)
	Excellent	Good	Fair	Bad	
Treated	47	6	1	0	98.15
Control	44	8	1	1	96.30

Experimental example 6 Pharmacodynamic experiment of the curative effect of the capsule made from the leaf of *Cajanus cajan* on treating ischemic necrosis of caput femoris

1. Object: To evaluate the pharmacodynamic effect of Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule) on treating hormone-induced ischemic necrosis of caput femoris
2. Method: A model of ischemic necrosis of caput femoris of the invention was made on New Zealand rabbits induced by horse blood sera plus hormone. The establishment of the model was identified after 5 months. Then the model rabbits were administered Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule) at higher, middle and lower dosages respectively. Normal control and model control groups were set up at the same time. The animals were killed 8 weeks after the administration. The therapy effect was evaluated by the examination of amplified X-ray photo, bone density, optical microscope, electron microscope, bone metabolic dynamics et al.
3. Results: (1)Horse blood sera plus hormone can produce a typical model of ischemic necrosis of caput femoris;(2)Pharmacodynamic experiment indicated that: (i)The amplified X-rays picture showed that the conformation of Shengmaichenggu Capsule-treated groups at higher and middle dosage were nearly normal. For the model group, the bone density of proximal thighbone was not even. It showed a necrosis appearance; (ii) It could be seen under an optical microscope that the bone cavity rate in the caput femoris decreased for every dosage groups, meanwhile the counting numbers of both blood vessels and osteoblasts increased. There was a significant difference as compared with the model group($P<0.05$); (iii) It could be seen under an electron microscope that there had an abundance of functional organelles in the osteoblasts for every dosage groups, and the bone cells were mainly

in osteoplastic phase and resorptional phase; (iv)The bone density of proximal thighbone of lower dosage group was higher than that of other groups, and there was a significant difference as compared with the model group and the normal control group($P<0.05$). (v) The bone metabolic dynamics: The bone growth values of higher and lower dosage groups increased significantly as compared with that of the model group($P<0.05$); (vi)Blood biochemistry indexes :The level of total cholesterol and triglyceride in serum had no significant difference among these groups.

4. Conclusion: Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule) has significant effect on treating hormone-induced ischemic necrosis of caput femoris. The main mechanism is promoting the restoration and regeneration of blood vessels in bony tissue and marrow ,and promoting the growth of new bone.

Experimental example 7 Test of the effect of the capsule made from the leaves of Cajanus cajan on optimizing hermorheology index of rat acute blood stasis model

1. Experimental materials

Medicaments: Shengmaichenggu Capsule (Pulse-facilitation and bone-formation Capsule); Epinephrine hydrochloride injection 1mg/ml, supplied by Min Sheng pharmaceutical manufactory, Hangzhou, lot number: 951012; Tetramethylpyrazine phosphate, supplied by Shi Qiao pharmaceutical manufactory, Guangzhou, lot number : 950116; Pentobarbital sodium, lot number: 950202.

Animals: 60 male SD rats, body weight 150-200g , supplied by the animal feedlot of the Health Department of Guangdong Province. Certificate number: 96A02.

2. Method and results

the rats were divided into 6 groups randomly , i.e. normal control group, blood stasis model group, Tetramethylpyrazine phosphate-treated group and three Shengmaichenggu capsule-treated groups (the dosage were shown in table 9). the control group and the blood stasis model group were administered equal volume of distilled water by gavage. every treated groups were administered liquor drug with different concentrations at a dosage of 2ml/100g weight /day, once daily at a fixed time for 20 days. When 24 hours after the last administration, animals except the normal control group were injected epinephrine hydrochloride hypodermically for two times(0.8mg/kg) with an interval of 3 hours. The rats were immersed in water at 4 ± 1 $^{\circ}\text{C}$ for 5 minutes at the time of 1.5 hour after the first injection of epinephrine hydrochloride, then the animals fast. In the next morning , eyeball blood was taken from anaesthetized animals (injected pentobarbital sodium to abdominal cavity at a dosage of 30mg/kg). Hermorheology indexes were determined which include specific viscosity of whole blood , specific viscosity of plasma, erythrocyte sedimentation and hematokrit .

Table 9 The effect of Shengmaichenggu capsule on hemorheology index of rat acute blood stasis model (x±s)

Group	Number of animal	Dosage/kg/day	Specific viscosity of whole blood		Specific viscosity of plasma	Erythrocyte sedimentation	Hematokrit
			Lower shear viscosity coefficient	Higher shear viscosity coefficient			
Control	10	20ml distilled water	18.83±1.10	5.43±0.30	1.87±0.10	1.40±1.43	42.60±1.35
blood stasis model	7	20ml distilled water 90mg	28.78±2.17**	6.44±0.19***	1.82±0.13	2.73±0.50***	45.86±3.85*
Tetramethylpyrazine phosphate	11		20.87±2.63###	5.59±0.40###	1.95±0.08	1.80±0.27##	43.55±2.39
Shengmaichenggu	8	7.68g	21.70±1.90###	5.64±0.26###	1.97±0.19	1.75±0.21##	43.38±2.88
Shengmaicenggu	9	3.84g	21.88±2.53###	5.83±0.37###	1.99±0.20#	1.99±0.24#	43.67±1.58
Shengmaicenggu	12	1.92g	24.07±1.74###	6.01±0.33##	2.05±0.19##	2.19±0.45	45.75±3.28

3. Results

The specific viscosity of whole blood, erythrocyte sedimentation and hematokrit in blood stasis model group increased significantly compared with those of normal control group, ($p<0.05$, $p<0.01$). The specific viscosity of whole blood and erythrocyte sedimentation in tetramethylpyrazine-treated group and Shengmaichenggu capsule-treated group decreased significantly compared with those of model group. The specific viscosity of plasma of Shengmaichenggu capsule-treated group at middle and lower dosage decreased significantly as compared with that of the model group($P<0.01$ or $P<0.05$). The two experiments above-mentioned indicated that Shengmaichenggu capsule (Pulse-facilitation and bone-formation capsule) has the effect of promoting blood circulation and removing blood stasis.

Experimental example 8 The analgesic effect of the capsule made from the leaves of *Cajanus cajan*

1. Experiment of writhing response on mouse

(1) Experimental materials

Medicaments: Shengmaicenggu capsule (Pulse-facilitation and bone-formation capsule); indometacin, supplied by Guangdong Shiqi pharmaceutical manufactory, lot number: 950306; 0.6% acetic acid, lot number: 951025.

Animals: 42 NIH mice weighting 18-22g each mouse, including male and female by half and half, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A03.

(2) Experimental method

Divided the mice into 5 groups randomly, i.e. control group (0.2ml/10g distilled water), indometacin-treated group (0.013g/kg) and three Shengmaichenggu capsule-treated groups (dosages are shown in table 10). The mice were administered by gavage for 7 days. At the time of 60 minutes after the administration at the day 7, injected 0.6% acetic acid to abdominal cavity of the mice (0.2ml/one mouse). Recorded the first time when the writhing response appeared caused by pain for each mouse, the number of the writhing response appeared in 10 minute and the analgesic percent. The results were analyzed statistically and shown in table 10.

Table 10 The analgesic effect of Shengmaichenggu capsule on mouse (writhing response) ($x\pm s$)

Group	Number of animal	Dosage /kg/day	The First time when the writhing response appeared(s)	Number of writhing mice	Analgesic percent (%)
Control	8	20ml distilled water	214.75±47.74	8	0
Indometacin	8	0.013g	572.75±182.13###	2##	75##
Shengmaichenggu	8	10.24g	476.75±150.43###	3##	62.5##
Shengmaichenggu	9	5.12g	454.22±128.17###	3##	62.5##
Shengmaichenggu	9	2.56g	327.56±118.25	4	50

Comparing with the control group, for the group marked with # $P<0.05$, for group with ## $P<0.01$, for group with ### $P<0.001$

(3) Experimental results

Comparing with the normal control group, the time when the writhing response first appeared postponed significantly in the indometacin-treated group and the Shengmaichenggu capsule-treated groups with higher and middle dosage ($P<0.001$). The number of writhing mice decreased ($P<0.01$) and the analgesic percents increased($P<0.01$). The results indicated that Shengmaichenggu capsule has analgesic effect on mouse pain induced by acetic acid.

3. Hot-plate test on mouse

(1)Experimental materials

Medicaments:Shengmaichenggu capsule; indometacin, supplied by Guangdong Shiqi pharmaceutical manufactory, lot number : 950306.

Animal:75 NIH female mice weighting 18-22g each mouse, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A03.

(2)Method

Adjusted the temperature of water bath box to $55^{\circ}\text{C} \pm 1^{\circ}\text{C}$. Immersed one big beaker in the water bath and put mice into the beaker. Recorded the period from the time when animals were put into the beaker to that when animals licked feet due to pain, and defined the period as the threshold of pain of that mouse.

Screened out the mice whose threshold of pain were in the range of 5-30 seconds , and divided them randomly into 5 groups including control group, indometacin-treated group and three Shengmaichenggu capsule-treated groups(The dosage are shown in table 11). Administered medicaments to animals by gavage for continuous 7 days. Determined the threshold of pain at the time of 30 minutes and 60 minutes after the administration at day 7 respectively, and observed the changes in the threshold of pain after administration. Room temperature should be controlled in the range of $15\text{-}20^{\circ}\text{C}$.

(3)Results

Table 11 The analgesic effect of Shengmaichenggu capsule on mouse (hot-plate test) ($\text{x} \pm \text{s}$)

Group	Number of animal	Dosage/kg/day	Threshold of pain before administration (S)	Threshold of pain at different time after administration (S)	
				30min	60min
Control	15	20ml	18.80 \pm 4.77	16.93 \pm 4.42	16.47 \pm 4.69
Indometacin	14	0.013g	18.93 \pm 5.41	28.07 \pm 6.67###	24.64 \pm 6.49###
Shengmaichenggu	15	10.24g	17.00 \pm 4.583	21.27 \pm 4.43	24.53 \pm 6.12###
Shengmaichenggu	15	5.12g	17.60 \pm 4.92	24.67 \pm 7.26##	21.27 \pm 4.04#
Shengmaichenggu	15	2.56g	18.80 \pm 4.14	20.20 \pm 3.43	22.53 \pm 6.82##

Note:Comparing with the control group ,for the group marked with #P<0.05,for group with ## P<0.01, for group with ###P<0.001.

The experimental results are shown in table 11. It can be seen that the threshold of pain before administration has no significant difference among these groups. 30 minutes after administration, the threshold of pain of indometacin -treated group and Shengmaichenggu capsule-treated group at middle dosage increased significantly as compared with that of the control group(P<0.01 or P<0.001). 60 minutes after administration, the threshold of pain of indometacin -treated group and Shengmaichenggu capsule-treated group at higher ,middle and lower dosage increased significantly as compared with that of the control group (P<0.05, P<0.01 or P<0.001).

Experimental example 9 The antiphlogistic and antioncotic effect of the capsule made from the leaves of Cajanus cajan

1.Experiment of the mouse pinna inflammation induced by dimethylbenzene

(1)Experimental materials

Medicament: Shengmaichenggu capsule;

Animals: 40 NIH mice weighting 18-22g each mouse, supplied by the animal feedlot of the Health Department of Guangdong Province,Certificate number: 96A03.

(2)Method

Divided the mice into 5 groups randomly with 8 mice each, i.e. control group, indometacin-treated group and three Shengmaichenggu capsule-treated groups(dosages are shown in table 12).The mice were administered medicaments in different concentration by

gavage. In the morning of day 7, 30 minutes after administration, pressed tampon soaked with dimethylbenzene on the left ear for about 5 seconds. Killed the mice after 15 seconds by decollation. Cut out the equal area at the same position from both ears of the mouse with perforator, and weighted with torsion balance. The swell degree is defined as the weight difference of subtracting the weight of the right ear from that of the left. Analyzed the data of swell degree of the control group and the treated groups statistically.

(3) Experimental results

Table 12 The effect of Shengmaichenggu capsule on mouse pinnal inflammation caused by dimethylbenzene (x±s)

Group	Number of animal	Dosage/kg/day	Swell degree (mg)
Control	8	20ml distilled water	0.8375±0.3378
Indometacin	8	0.013g	0.5500±0.258
Shengmaichenggu	8	10.24g	0.3500±0.1195##
Shengmaichenggu	8	5.12g	0.8125±0.5768
Shengmaichenggu	8	2.56g	0.4875±0.2167#

Note: Comparing with the control group, for the group marked with #P<0.05, for group with ## P<0.01

The experimental results are shown in table 12. It can be seen that the swell degree of Shengmaichenggu capsule-treated groups at higher and lower dosage decreased significantly as compared with that of the control group (P<0.05 或 P<0.01). The results indicate that Shengmaichenggu capsule can inhibit mouse pinnal inflammation caused by dimethylbenzene.

2. Test of granuloma induced by tampon on rat

(1) Experimental materials

Medicaments: Shengmaichenggu capsule; prednisone acetate, supplied by Xianju pharmaceutical Co. Ltd., Lot number: 950523.

Animals: 60 SD rats, body weight 150-200g, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A02.

(2) Method

The rats were divided into 5 groups randomly with 12 rats each group, i.e. control group, prednisone acetate-treated group and three Shengmaichenggu capsule-treated groups. An incision was made aseptically along the dorsomeson of a rat anaesthetized by pentobarital sodium and a sterilized tampon was imbedded into the incision and sewed up. The treated groups were administered by gavage 3 days before surgery until the day 7 after surgery. At the 8th day after surgery, the rats were killed by decollation. Avulsed out the tampon-caused granuloma tissue and dried it at 60-90°C in a oven for 1 hour. Then weighted and subtracted the initial weight of tampon to get the net weight of granuloma tissue. Compared the granuloma weight among these groups and analyzed the results statistically.

(3) Results

Table 13 The effect of Shengmaichenggu capsule on tampon-induced granuloma of rat (x±s)

Group	Number of animal	Dosage/kg/day	Net weight of granuloma (mg)
Control	12	20ml distilled water	64.29±6.72
Prednisone acetate	12	25mg	33.45±13.10##
Shengmaichenggu	12	7.68g	56.24±6.12#
Shengmaichenggu	11	3.84g	56.41±8.14#
Shengmaichenggu	12	1.92g	52.37±10.58##

Note: Comparing with the control group, for the group marked with #P<0.05, for the group with ## P<0.01, for the group with ### P<0.001

The experimental results are shown in table 13. It can be seen that the net weight of granuloma of prednisone acetate-treated group and the three Shengmaichenggu

capsule-treated groups at every dosage decreased significantly as compared with that of the control group($P<0.05$ or $P<0.01$). The results indicate that Shengmaichenggu capsule can inhibit granuloma.

Experimental example 10 Immunity potentiating effect of the capsule made from the leaves of *Cajanus cajan*

1.Experiment of nonspecific immunological functions

(1). Experimental materials

Medicaments:Shengmaichenggu capsule; levamisole , supplied by Guangdong Shiqi pharmaceutical manufactory , lot number: 950406; prednisone acetate , supplied by Xianju pharmaceutical Co. Ltd., Lot number: 950523.

Animals: 65 NIH mice weighting 18-22g each mouse, including male and female by half and half, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A03.

(2). Methods:

The mice were divided into 6 groups randomly ,i.e. control group , modeled group, levamisole-treated group, and three Shengmaichenggu capsule-treated groups(dosages are shown in table 14). The modeled group, levamisole-treated group and three Shengmaichenggu capsule-treated groups were administered 0.3% prednisone acetate at a dosage of 0.2ml/10g body weight by gavage for continuous 7 days. Meanwhile administered different medicaments to these groups by gavage for continuous 20 days respectively. Administered distilled water to the control group by gavage in the same period . At the time of 30 minutes after administering on the day 20, injected Zhonghua china ink into tail vein at a dosage of 0.01ml/10g. At the 2th and 12th minute after injection, took 10 ul orbit blood and put into 3ml 0.1% Na_2CO_3 solution and shook up. Detected optical density(OD) by colorimetric analysis in 722-grating photometer($\lambda=620$). Calculated phagocytic index K and phagocytic index α according to the following equation :

$$K = \frac{\log OD_1 - \log OD_2}{T_2 - T_1}$$

$$X = \frac{W}{WLS} \sqrt[3]{K}$$

OD is the optical density of blood samples taken at different times, $T_2 - T_1$ is the difference between the two sampling times, W is body weight , WLS is the total weight of liver and spleen . for the results were made by statistical analysis. The animals were killed by dislocating cervical vertebra. The liver and spleen were weighted respectively. Determined the weight of immune organs of every mouse according to the immune organ weighting method. Calculated the immune organ index and made a statistical analysis for the result.

(3) Experimental results

Table 14 Effect of Shengmaichenggu capsule on the monocytophagous function of mouse

Group	Number of animal	Dosage/kg/day	Phagocytic count K	Phagocytic activity α
Normal control	10	20ml distilled water	0.0374±0.0143	5.2784±0.9169
modeled	12	20ml distilled water	0.0187±0.00582*	4.7002±0.6249
Levamisole	12	0.04g	0.0273±0.00852	5.1964±0.7761
Shengmaichenggu	13	10.24g	0.0259±0.0135	5.2355±1.2854
Shengmaichenggu	9	5.12g	0.0216±0.0112	4.7861±1.1155

Shengmaichenggu	9	2.56g	0.0207±0.0071	5.3286±0.8556
-----------------	---	-------	---------------	---------------

Table 14 shows the effect of Shengmaichenggu capsule on the monocytophagous function of mouse. It can be seen that the count k of the model group decreases significantly as compared with that of the control group, α and K of the Shengmaichenggu capsule-treated groups at every dosages have an increasing trend.

Table 15 Effect of Shengmaichenggu capsule on the immune organs of mouse

Group	Number of animal	Dosage/kg/day	Immune organ coefficient (mg/kg)	
			Thymus (x±s)	Spleen (x±s)
Control	11	20ml	2.772±0.875	61.83±1.908
Model	12	20ml	1.114±0.268***	41.08±1.081***
Levamisole	12	0.04	1.501±0.334#	52.82±0.887###
Shengmaichenggu	12	10.24	1.764±0.271###	54.75±1.758###
Shengmaichenggu	11	5.12	1.425±0.133###	47.56±1.758###
Shengmaichenggu	11	2.56	1.201±0.207	40.11±0.887

Table 15 shows the effect of Shengmaichenggu capsule on the immune organs of mouse. It can be seen that Shengmaichenggu capsule (Pulse-facilitation and bone-formation capsule) at both higher and middle dosage can improve the weight of thymus and spleen significantly ($P<0.01$ 或 $P<0.001$). This indicates that Shengmaichenggu capsule (Pulse-facilitation and bone-formation capsule) can improve the mouse nonspecific immunological function and antagonise immunosuppression.

2. Experiment of the content of mouse hemolysin

(1). Experimental materials

Medicaments: Shengmaichenggu capsule; Levamisole , supplied by Guangdong Shiqi pharmaceutical manufactory , lot number: 950406; Prednisone acetate , supplied by Xianju pharmaceutical Co. Ltd., Lot number: 950523; 5% Suspension of chicken red blood cells in physiological saline; 10% Complement (Physiological saline :Mouse serum =3:2)

Animals: 60 NIH mice weighting 18-22g each mouse, including male and female by half and half, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A03.

(2) Experimental method

The grouping and administering scheme was the same as that of the above-mentioned Experiment of nonspecific immunological functions. At the first day of administration, injected 5% suspension of chicken red blood cells to abdominal cavity of mice at a dosage of 0.2 ml/one mouse. Seven days after immunization, took blood from eyeball and centrifuged. The serum was diluted 100 times with physiological saline. 1 ml of the diluted serum was mixed with 0.5ml of 5% suspension of chicken red blood cells and 0.5 ml of 10% complement. After incubation in an incubator at 37°C for 30 minutes , the reaction was terminated by putting the mixture into a 0°C refrigerator .

The formulated test solution was centrifuged. Took the supernatant and detected optical density(OD) by colorimetric analysis in 722-grating photometer($\lambda =620$). Set up a control group free of serum and took the supernatant of the centrifuged test solution of this group as the "0" basis for colorimetric assay . Took "OD" as the index for quantifying the serum hemolysin and analysed the data statistically.

(3). Experimental results

Table 16 Effect of Shengmaichenggu capsule on the hemolysin content of mouse immunised by chicken blood cells (x±s)

Group	Number of case	Dosage/kg/day	OD(Optical density)
Control	10	20ml distilled water	0.9083±0.1790
Model	10	20ml distilled water	0.5055±0.1488***
Levamisole	10	0.04g	0.7370±0.1444
Shengmaichenggu	10	10.24g	0.6820±0.33802
Shengmaichenggu	10	5.12g	0.8180±0.3441#
Shengmaichenggu	10	2.56g	0.8110±0.3072#

From the experimental results shown in table 6, it can be seen that the "OD" values of the model group decrease significantly as compared with that of the control group($P<0.001$). This indicates that prednisone acetate can reduce the hemolysin content of mouse immunized by chicken blood cells. The "OD" values of Shengmaichenggu capsule-treated groups at middle and lower dosages increase significantly as compared with that of the model group($P<0.05$ or $P<0.01$). This indicates that Shengmaichenggu capsule can increase the hemolysin content of mouse immunized by chicken blood cells when it is immunosuppressed by prednisone acetate and improve the mouse humoral immunological function and antagonise immunosuppression.

3. Cellular immunity test

(1). Experimental materials

Medicaments: Shengmaichenggu capsule; Levamisole , supplied by Guangdong Shiqi pharmaceutical manufactory , lot number: 950406; PHA (Phytohaemagglutinin) , supplied by Biology Department of Jinan University, Lot number: 960611; 5% Suspension of chicken red blood cells in physiological saline; 10% Complement (Physiological saline :Mouse serum=3:2).

Animals: 60 NIH mice weighting 18-22g each mouse, including male and female by half and half, supplied by the animal feedlot of the Health Department of Guangdong Province, Certificate number: 96A03.

(2). Experimental method

The mice were divided into 6 groups randomly ,i.e. control group , model group , levamisole-treated group , and three Shengmaichenggu capsule-treated groups at different dosages(dosages are shown in table 17). Administered by gavage once a day for continuous 7 days. After the last administration, all the animals were immunized by injecting 5% suspension of chicken red blood cells to abdominal cavity at a dosage of 0.2 ml/one mouse. Then the animals were injected PHA to abdominal cavity at a dosage of 0.025 ml/10g for continuous 3 days. All groups except control group were administered prednisone acetate at a dosage of 3g/kg body weight by gavage for continuous 7 days. At the time of 12 hours after last administration, the experiment was carried out according to the Experiment of the content of mouse hemolysin mentioned above in which chicken blood cells were used as immunogen.

(3)the result of the test

Tab 17. The effect of Shengmaichenggu capsule on the transformation reaction of mice lymphocyte

Groups	animals	Dosage/kg/day	limphoblast(%)	transition state cells(%)	Transformation rate of lymphocyte (%)
Normal control	10	distilled water 20ml	0.2390±0.04725	0.2890±0.02726	0.5280±0.03458
Model	10	distilled water 20ml	0.2010±0.03929	0.2320±0.03736 ^{**}	0.4330±0.03561 ^{***}
Levamisole	10	0.04g	0.4310±0.05043 ^{###}	0.3050±0.04950 ^{###}	0.7370±0.03234 ^{###}
Shengmaichenggu capsule	10	10.24g	0.3650±0.1083 ^{###}	0.2740±0.04766 ^d	0.6390±0.07795 ^{###}
Shengmaichenggu capsule	10	5.12g	0.3350±0.05297 ^{###}	0.2530±0.03401 [#]	0.5870±0.03561 ^{##}
Shengmaichenggu capsule	10	2.56g	0.4000±0.06218 ^{##}	0.2750±0.04720 [#]	0.6750±0.03923 ^{##}

The result was shown in Tab 17, which suggested that the transition state cells and the transformation rate of lymphocyte in the model group was reduced significantly as compared with that of the control group ($p<0.01$ or $p<0.001$), and there is a reductive trend for the limphoblast of the model group as compared with that of the control group ; the limphoblast and the transformation rate of lymphocyte of the three Shengmaichenggu Capsule groups and the Levamisole group were increased significantly as compared with that of the model group ($p<0.001$). The transition state cells of the Shengmaichenggu Capsule groups at higher and lower dosage and the levamisole group were increased significantly as compared that of model group ($p<0.05$), which suggested that the Shengmaichenggu Capsule can enhance the cellular immunity function of the mice.

Example 11 The clinical research of the combination effect of the leaves of Cajanus Cajan(L.) Millsp and the extract thereof on bed sore.

1. Medicaments

The leaves of Cajanus Cajan(L.) Millsp and the extract thereof ; Shengji Ointment composed of zinc oxide, borneol, massicot, phenol, vaselin, acidum boricum and the like, which was the experiential formulation for treating the wound infection for more than 30 years used by the arthroosteopedic surgery and the surgical department of the First Affiliated Hospital of Guangzhou University Of Traditional Chinese Medicine.

2. Standard

(1) The standard of dividing the stages of bed sore: According to the standard of dividing and judging the stages of bed sore which was defined in the probative text book *basic nursing* for the national middle medicine schools.

The first stage is the florid stage of blood stasis : Temporary blood circulatory disorder (reactive blood stasis) appears when the local skin was pressed. The symptom is that the skin becomes red, swelling, ardent, and aching.

The second stage is the stage of inflammatory infiltration: The red and swelling part infiltrates outward, expands, and transforms. The color of skin becomes black and the blebs appears on the surface. The patient felt painful.

The third stage is the stage of the superficial ulcer: The blebs are disrupted, the local site is infected, the superficial tissue necroses, and the ulcer is formed.

The forth stage is the stage of necrotic ulcer: The necrotic tissue invaded the lower layer of cutis vera and muscular layer. ligament becomes visible and there is more pus. The necrotic tissue is black, graveoleat and caducous. The infection expands toward peripheral and deep tissues, even to bones, which can seriously cause pyemia.

(2)The method standard for calculating bed sore: 1) Area: The area is calculated by the way of computing the area of the plane geometric graph. 2) Time index for bed sore

healing : Time index for bed sore healing—(the area of bed sore \times the course of bed sore)/days for bed sore healing.

(3) The standard of evaluating the effect: 1) healing time: days from the day of initial administration to the day when the wound is cured completely. 2)healing standard:The wound surface was covered by endepidemis ,and the wound disappeared completely.

(4) The inclusion standard of cases: 1) Disease type: only the bed sore patients suffering from craniocerebral injury, lower extremities fracture and spinal column injury with paraplegia are included. 2) Site: Only the cases of sacrococcygeal bed sore are included. 3) inclusion standard for dividing the bed sore stages: Patients whose symptoms met the requirements of standard 1), 2) and beyond bed sore' second period. 4) Age and sex: Patients who met the requirements of standard 1), 2) and 3) can be included in spite of their age and sex.

(5) The exclusion Standard of cases: The cases of infection of burn with ulcer or furunculous abscess and sacrococcygeal infections caused by tuberculosis and hemorrhoidal ulcer are excluded.

3. Therapeutic method

(1) Cleaning the wound: Bed sore wound was cleaned according to its condition. After general disinfection, all the necrose and inactivate soft tissues and dead bones were eliminated until the staxis of soft tissues and the facies ossea occurred. Then the wound was washed with aquae hydrogenii dioxidi or Eusol and normal saline.

(2)Changing the dressings: The surface of the cleaned wound was covered with the Shengji Ointment or the leaves of Cajanus Cajan(L.) Millsp and the extract thereof. Change the dressings once a day wherein the used drugs were removed and the new drugs were applied according to the general rules of changing the dressings. When there was new epidermis on the wound, the drugs were changed once every three to four days.

4. the general condition of the patients in the two groups

(1) The group of the leaves of Cajanus Cajan(L.) Millsp and the extract thereof: 34 men and 16 women aged from 19 to 86. The maximum area of the bed sore was 19cm \times 12cm(Stage IV), the minimum was 2cm \times 1cm(Stage II) and the average was 17.5cm 2 .

(2) The Shengji Ointment group : 22 men and 17 women aged from 19 to 90. The maximum area of the bed sore was 8cm \times 7cm(Stage IV), the minimum was 2cm \times 1cm(Stage II) and the average area was 9.9 cm 2 .

5. the result:

(1) the bed sore healing time of the two groups was contrasted

As was showed in Tab.18, the bed sore healing time of the group of the leaves of Cajanus Cajan(L.) Millsp and the extract thereof was 14 days ($p<0.01$) less than that of the Shengji Ointment group. The difference was significant.

Tab.18 the contrasted bed sore healing time between the two groups ($x \pm s$)

Groups	Cases	Healing days
Cajanus Cajan(L.) Millsp	50	28.16 \pm 16.72
Shengji Ointment	39	44.54 \pm 30.49

(2) the contrasted bed sore healing time(days) in different stages

As was shown in Tab.19, the difference of the healing time between the groups was not significant, which suggested that the curative effect of two groups was almost the same.

Tab.19 contrasted healing time from the medium state to the stage when bed sore was cured between two groups ($\bar{x} \pm s$)

groups	Cases of stage II	Cases of Stage III	Cases of Stage IV
Cajanus Cajan(L.) Millsp	12.30±8.02(12)	26.90±12.37(23)	43.14±14.06(15)
Shengji Ointment group	18.50±7.2(13)	44.20±16.41(18)	87.50±30.41(8)
	P<0.05	P<0.001	P<0.01

(3) the contrasted bed sore healing time index

Tab.20 the contrasted bed sore healing time index between the two groups ($\bar{x} \pm s$)

groups	Total index	Stage II	Stage III	Stage IV
Cajanus Cajan(L.) Millsp	1.47±1.18	0.87±0.34	1.21±0.84	2.33±1.57
Shengji Ointment group	0.74±0.35	0.52±0.16	0.71±0.31	1.06±0.52
	P<0.01	P<0.01	P<0.01	P<0.01

It is the more scientific and accurate way to evaluate the effect of drugs by calculating the healing time as a control. The larger the time index is, the more effective the drug is, and vice versa. The difference of the bed sore healing time index between the two groups was shown in Tab. 20 which suggested that the leaves of Cajanus Cajan(L.) Millsp and the extract thereof had reliable and excellent effect on bed sore.

When the bone in the bed sore site is exposed in the clinic observation, administration of drugs made from Cajanus Cajan(L.) Millsp and the extract thereof would make several small pannus appear on the exposed surface of the bone, which is then grown into granulation, and jointed into a flake together with the granulation which was grown from edge to the central, forming the new granulation tissue to cover the wound surface. However this phenomenon was not observed in the Shengji Ointment group, wherein the granulation tissue sprawled slowly from ambitus to the central and was hard to cover the bare bones, so it is necessary to chose other extracts for antibacterial effect. As indicated above, among cases using drugs made from leaves of Cajanus Cajan(L.) Millsp and the extract thereof, the granulation tissue on bed sore wound surface formed faster and covered wound surface more quickly while wound secretion was relatively less. The leaves of Cajanus Cajan(L.) Millsp and the extract thereof was also confirmed to have better antibacterial effect on staphylococcus aureus by in vitro antibacterial test, which was equal to that of gentamicin (plant paper test). And the animal test also proved its antibacterial effect on acute, subacute and chronic inflammation model. The adverse effect of the drug was never appeared during the clinical use and the patients were response well.

Example 12. The clinical research of the effect of the leaves of Cajanus Cajan(L.) Millsp and the extract thereof on the infected wound caused by open fracture

1.Clinical information

18 cases were chosen aged from 14 to 70, wherein 6 cases suffered from wound, 7 cases experienced immobilization surgery after being wounded, 3 cases experienced amputation, and 2 cases suffered from gangrene dismemberment. Among them there were 8 cases with fracture at the position of lower 1/3 of the tibia and fibula, 2 cases with fracture at the upper 1/3 of the tibia and fibula, and 2 cases with fracture at the lower 1/3 of the femora.

2.therapeutic method

Only the drugs made from leaves of Cajanus Cajan(L.) Millsp and the extract thereof were used to be spread on the surface of the wounded site for all the cases. The drug has a concentration of 1:2 (i.e. the aqueous solution with a concentration of 1:2 prepared by the leaves of Cajanus Cajan(L.) Millsp and the extract thereof and the distilled water for

injection), PH of 5.3, and was packed in bottles after disinfection. The operation should meet asepsis requirement when changing used drugs with new drugs. The wound surface was sopped with a piece of carbasus which had been soaked in the drug solution before use, and covered and bandaged with vaseline carbasus and sterilized dressing. When the wound infection was obvious, the administration was carried out once a day; when the granulation tissue appeared and the exudatum was reduced, the administration was carried out twice a day; when wound surface was covered by new granulation tissue completely, it was changed to use the mixed solution of gentamycin and normal saline to perform hydropathic compress. After three days, free skin grafting was operated with pieces of medium pachydema. Three days after operation, the Chinese herbs were continued to used for performing hydropathic compress until the wound was cured.

3. Observation items:

In order to observe the change of the wound surface we took the dynamic color image during different time before and after the administration. The germiculture and the drug sensitivity test were carried out for the secretion on the wound surface; The occurring time, developing rules and the growth condition of epithelial granulation tissue, the granulation islands, and the wound surface's healing time were observed. The histological inspection of granulation on the wounded surface was also observed.

4. the result

In the clinical test, 15 cases' infection was controlled during 3 days, other 3 cases' infection would be controlled after extirpating dead bones caused by its long time infection with bones infection and bones necrosis. The exudatum was reduced quickly after the administration, and the granulation tissue occurred 2 to 5 days after the administration. It was scarlet and easy to bleed if touched. The granulation tissue could cover the wound surface when it extended to the edge skin of the wound.

5. conclusion

The leaves of *Cajanus Cajan*(L.) Millsp and the extract thereof had better anti-infective effect on clinical infected wound surface and could enhance the growth of the granulation tissue. It also increased the blood supply of the wound surface and accelerated the agglutination of the wound. Especially, it could make granulation tissue which was called *bone granulation islands* grow on the bone which was exposed to the wound surface

Example 13. the effect of the leaves of *Cajanus Cajan*(L.) Millsp and the extract thereof on the healing of the open infected wound surface

1. The effect of leaves of *Cajanus Cajan*(L.) Millsp and the extract thereof on agglutination of open infected wound surface

(1)Experiment materials

The solution of the leaves of *Cajanus Cajan*(L.) Millsp and the extract thereof with the concentration of 1:2 (i.e. the aqueous solution with the concentration of 1:2 prepared by the leaves of *Cajanus Cajan*(L.) Millsp and the extract thereof and the distilled water for injection), PH 5.3, which was packed in bottles after disinfection.

The model of wound infection on the rabbits' two fore-legs was established as follow: 19 healthy rabbits with the body weight of 2-2.8kg were selected no matter what sexuality they were. The animal were divided into three groups to establish the model of the two fore-legs' open wound surface, then inoculated with bacterium. It was proved by pro-test that the infection of wound surface approached to the peak at 72 hours later after inoculation.

(2)drug application

The drug was applied on the surface of the infection, wherein the drug was applied

- twice a day for the first week, once a day from the second week to the time when the wound surface was substantially cured, and once every three days when the wound surface was substantially cured or cured completely. It should be ensured the applied dosage was the same. Furacilin was used as the control.

(3) the method for observing and evaluating indicators

The determination was carried out once every three days by describing the edge of the wound surface during the time when the wound surface was formed, before and after the administration. The healing time of the wound surface was determined by statistically processing the curve graph for the area of the wound surface versus the time and the value of the area for every group at every time; and checking the wound epidermis and the granulation tissue and scar tissue both visually and by optical microscope

(4) the result of the test

The renovating effect of the leaves of *Cajanus Cajan(L.) Millsp* and the extract thereof on the wound surface was superior to that of control group after 9 days of administration. The eventual healing time of wound was about one week ahead of that of the control, which showed a significant difference ($p<0.05$).

(5) conclusion

The leaves of *Cajanus Cajan(L.) Millsp* and the extract thereof have the effects of enhancing the growth of granulation tissue on the wound surface, increasing the blood supply of the wound surface, accelerating the agglutination of the wound, decreasing the formation of scar and improving the quality of agglutination of wound.

2. The anti-infection effect of Leaves of *Cajanus Cajan(L.) Millsp.* and extract thereof on open infected surface of wound

(1) Experimental material

The solution of the leaves of *Cajanus Cajan(L.) Millsp* and the extract thereof with the concentration of 1:2 (i.e. the aqueous solution with the concentration of 1:2 prepared by the leaves of *Cajanus Cajan(L.) Millsp* and the extract thereof and the distilled water for injection), PH 5.3, which was packed in bottles after disinfection.

The model of wound infection on the rabbits' two fore-legs was established as follow: 6 healthy rabbits with the body weight of 2.5-3kg were selected no matter what sexuality they were. The animal were divided into three groups to establish the model of the two fore-legs' open wound surface, then inoculated with bacterium and concentration of bacterium was increased to 9 hundred million bacteria/ml. It was proved by pro-test that the infection of wound surface approached the peak at 36 hours after inoculation.

(2) Application of medicament

The above medicament was used externally when the infection of wound surface approached the peak, administrated twice per day(8 AM and 4 PM each), normal saline used as control.

(3) Observation item

The dynamic color images of the surface of wound was taken before administration and at the different time of administrating. The infectious change of the surface of wound was observed; The range of aula ring and color variation around the surface of wound was observed, and the congestion state of the surface of wound was found out. The degree of peripheral tumid and the amount change of secretion on the surface of wound were observed so that the exudation state of the surface of wound can be known.

(4) Experimental result

The renovation effect of Leaves of *Cajanus Cajan(L.) Millsp.* and the extract thereof on surface of wound was superior to that of control group after 9 days of administration. The final healing time was about one week ahead of that of the control group, which showed a significant difference ($p<0.05$).

• (5)Experimental conclusion

The Leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof have good effect of anti-infection on infected surface of wound which was indicated by that the surface of wound and inflammatory response regressed quickly, especially the exudation of the surface of wound reduced soon and the wound became clean after administration. This showed that the medicament possess the favorable effect of anti-inflammatory exudation.

Experimental example 14

The curative effect observation of Leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof applying to 564 cases with infected surface wound.

1.Clinical information

Leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof was applied clinically to the diseases such as traumatic surface, infected surface of wound, burn infection, bedsores etc. in the past more than 6 years, and the curative effect of 564 cases was observed.

2. Experimental method

The secretion of infected surface of wound was cultured for bacteria. Usually *Bacillus proteus* *pyocyaneus*, *Bacillus coli*, *Staphylococcus albus*, *staphylococcus aureus* *Rosenbach*, few *Bacillus subtilis*, *Bacillus aerogenes* are often applied. After the drugs made from Leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof were external applied on the infected surface of wound topically for 3-5 days, the secretion and odor reduced, putridinous tissue was dispelled fast, florid granulation surface of wound was appeared gradually. After the drugs of the invention was applied to the larger surface of wound for 2 weeks, the skin grafting can be conducted basically; skeletons were exposed, and granulation insulas were seen grown with Haversian system after administration, covered the surface of bone gradually; muscle tendon parts must be moistened by applying drug liquid in order to avoid necrosing.

3. Conventional preparation

(1)The fresh leaves of *Cajanus Cajan(L.)* Millsp. were cleaned and soaked in 1% bromo-geramine for 20 minutes, air dried, then pounded, spread on the surface of the wound directly, or one layer gauze was spread on the surface of the wound, then the drug was spread on the gauze, and the drug liquid could permeate the gauze and act on the surface of the wound, and afterwards the wound was bundled with dressing at outside surface. (2) The surface of the wound was wetted with 200% inspissant of leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof, the former method of (1) had better curative effect when both were compared. (3) The leaves of *Cajanus Cajan(L.)* Millsp. were boiled in water to get liquid, then the surface of the wound was soaked with the liquid for about 30 minutes.

4. Results

(1)The clinical effects of removing necrotic tissue and promoting tissue regeneration were observed for the leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof when they were applied on the infected surface of wound. Generally when 3-5 days external application, or 1 to 2 weeks external application for the larger surface of wound after administration, the secretion reduced markedly, odor disappeared quickly and the curative effect is satisfied relatively.

(2) After the leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof were externally applied, the grown granulation became florid without little edema. The grown granulation with the drugs of the invention was more florid and vigorous than that grown after Eusol solution, 1% rotten sodium phytate solution, normal saline etc. were externally applied. The effect of fresh leaves is better than the boiled liquid of the leaves. So it was considered

that leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof not only have the bactericidal and bacteriostatic effect, but also have the anti-inflammatory effect. probably they also have a nutrient factor of promoting cell growth. When the infected surface of wound after punctual skin grafting on burn wound was wetted with the solution made from leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof, not only the infection could be controlled, but also it could be observed that the grown rate of the grafted skin is faster than that of the grafted skin where the drug of the invention was not applied.

(3) Usually it was relative difficult to treat the infection under the scab of burn wound, or the infection resulted from grafting skin, especially the infection of *Bacillus aeruginosus* after grafting skin. But when the 200%solution made of the leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof were used to moistened the infected wound which was exposed half, the effect was better than that of wet dressing with antibiotics. There is no worry of resistance resulted from antibiotic.

INDUSTRIAL APPLICABILITY

The leaves of *Cajanus Cajan(L.)* Millsp. is a species legume vivacious plant planted in south subtropics, so its source is abundant, and the technology of the invention is easy to be popularized. The inventive method of preparing the extract of the leaves of *Cajanus Cajan(L.)* Millsp. is handy and easy-to-use. It was proved by animal experiment and clinical observation that the leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof have obvious curative effect on ischemic necrosis of femur head, osteoporosis, ameliorateing hemorheological index, the anti-inflammatory and analgesic, reinforcing immunological function, coronary heart disease angina, fracture, cerebral infarction, bedsores, infected surface of wound and the infected surface of wound of open fracture etc., and have powerful pharmacological effect. The Leaves of *Cajanus Cajan(L.)* Millsp. and the extract thereof as active component could be formulated into various clinical preparation such as tablet, pill, powder, capsule, oral liquid etc. by conventional preparation technique, and have favorable industrial applicability.

• Claims

- 1、A kind of extract of Leaves of *Cajanus Cajan(L.)* Millsp., characterized by that the extract is prepared by the following method: the medicinal material of Leaves of *Cajanus Cajan(L.)* Millsp. was placed in multifunctional extractor, and soaked in water in the amount of 10 times that of medicinal material for 0.5-2 hours, heated and decocted 1 to 4 times, every time for 1-2 hours, filtrated, the filtrate was taken out into the vacuum concentrator instantly ,concentrated to relative density 1.05-1.15(heat determined at 60°C) at degree of vacuum -0.08 Mpa and temperature 60°C, filtered with 80 mesh filter cloth, the filtrate was filtered by continuous centrifugation, the centrifugate was dried by spray drier, the dried powder was the extract of Leaves of *Cajanus Cajan(L.)* Millsp.
- 2、The extract of Leaves of *Cajanus Cajan(L.)* Millsp. according to claim 1, characterized in that Leaves of *Cajanus Cajan(L.)* Millsp. was soaked in water for 1 hour, heated and decocted 3 times, every time for 1.5 hours, centrifuged at 15000r.p.m and flow rate was 50L/hour, the temperature at the air inlet of the spray drier was 180°C, the dried time was 4 seconds , the temperature at air outlet was 80°C.
- 3、A pharmaceutical preparation, characterized in that Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof was pharmaceutical active component.
- 4、The use of leaves of *Cajanus Cajan(L.)* Millsp or extract thereof for the manufacture of a medicament for the treatment of osteoporosis
- 5、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of ischemic necrosis of caput femoris.
- 6、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the amelioration of hemorheological index.
- 7、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of anti-inflammatory and analgesic agent.
- 8、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the reinforcement of immunological function.
- 9、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of angina of coronary heart disease.
- 10、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of fracture.
- 11、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of cerebral infarction.
- 12、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of bedsore.
- 13、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of infected surface of wound.
- 14、The use of Leaves of *Cajanus Cajan(L.)* Millsp. or the extract thereof for the manufacture of a medicament for the treatment of the infected surface of wound of open fracture.

Attorney's Docket No.

?

Client's
Ref. No. 101113/US

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **THE LEAVES OF CAJANUS CAJAN(L) MILLSP AND EXTRACT, FORMULATION AND USES THEREOF**, the specification of which was described and claimed in PCT International Application No. PCT/CN00/00144 filed on June 19, 2000 and as amended under PCT Article 19 on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
China	99109886.2	July 20, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
China	99109147.7	June 18, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Y. Rocky Tsao, Reg. No. 34,053.
 Eric L. Prahl, Reg. No. 32,590.
 Harold H. Fox, Reg. No. 41,498

Frank R. Occhipinti, Reg. No. 35,306.
 John F. Hayden, Reg. No. 37,640

Address all telephone calls to Y. ROCKY TSAO at telephone number (617)542-5070.

Address all correspondence to Y. ROCKY TSAO at:

FISH & RICHARDSON P.C.
 225 Franklin Street
 Boston, Massachusetts 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Hao YUAN

Date: December 12, 2001

Inventor's Signature: _____
 Residence Address: Guangzhou City, Guangdong Province, P.R.China
 Citizenship: P.R. China CNY
 Post Office Address: Chinese Medicine Coxarthropathy Treatment Center of the Hospital Attached to Guangzhou Chinese Medicine University, No.10, Airport Road, Guangzhou City, Guangdong Province China 510405